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Compared with normal differentiated cells, cancer cells require a metabolic reprograming 
to support their high proliferation rates and survival. Aberrant choline metabolism is a 
fairly new metabolic hallmark reflecting the complex reciprocal interactions between 
oncogenic signaling and cellular metabolism. Alterations of the involved metabolic
network may be sustained by changes in activity of several choline transporters as well 
as of enzymes such as choline kinase-alpha (ChoK-α) and phosphatidylcholine-specific 
phospholipases C and D. Of note, the net outcome of these enzymatic alterations is an 
increase of phosphocholine and total choline-containing compounds, a “cholinic pheno-
type” that can be monitored in cancer by magnetic resonance spectroscopy. This review 
will highlight the molecular basis for targeting this pathway in epithelial ovarian cancer 
(EOC), a highly heterogeneous and lethal malignancy characterized by late diagnosis, 
frequent relapse, and development of chemoresistance. Modulation of ChoK-α expres-
sion impairs only EOC but not normal ovarian cells, thus supporting the hypothesis that 
“cholinic phenotype” is a peculiar feature of transformed cells and indicating ChoK-α 
targeting as a novel approach to improve efficacy of standard EOC chemotherapeutic 
treatments.
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inTRODUCTiOn
The uncontrolled cell growth characteristic of neoplastic diseases, besides involving deregulated 
control of cell proliferation, requires an adjustment of energy metabolism to sustain cell growth and 
division. Altered energy metabolism is considered as widespread in cancer cells as other cancer-
associated characteristics. Reprograming of cell metabolism has been therefore included among 
cancer hallmarks (1), a series of biological properties acquired by tumor cells during transformation 
and disease progression. Metabolites themselves can interfere with oncogenic-driven cell signaling 
(2) and, since cancer cells are dependent on these changes in metabolism, these altered pathways rep-
resent attractive sources of promising therapeutic targets (3, 4). Furthermore, the differential uptake 
in some human cancers of glucose, choline, acetate, methionine, and aminoacid analogs, when used 
FiGURe 1 | Schematic representation of PC cycle and routes of PCho accumulation. (A) Kennedy’s pathway: Cho, choline; Chok, choline kinase; PCho, 
phosphocholine; CCT, cytidylyltransferase; CDP-Cho, cytidine diphosphate-choline; PCT, phosphocholine phosphotransferase; DAG, diacylglycerol; PC: 
phosphatidylcholine. Catabolic pathways: PLC, PC-specific phospholipase C; PLD, PC-specific phospholipase D; PLA, PC-specific phospholipases A2 and A1; PD, 
phosphodiesterase; GPC, glycerophosphocholine; PA, phosphatidate. (B) In the progression from non-tumoral ovarian surface epithelial cells (OSE) or immortalized 
cell variants (IOSE with an increased replicative potential and IOSE-HTERT with unlimited replicative potential) to EOC cells, there is an evident accumulation of 
PCho (red arrows) and a decrease of GPC (green arrows).
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as radiotracers in positron emission tomography (PET) imaging, 
is considered a clinically useful diagnostic/staging tool (4).
CHOLine MeTABOLiSM ALTeRATiOn  
in HUMAn CAnCeR
Aberrant choline metabolism, characterized by increased phos-
phocholine (PCho) and total choline-containing compounds 
(tChos), is a fairly new metabolic hallmark that can be monitored 
in cancer by magnetic resonance spectroscopy (MRS) and that 
reflects the complex reciprocal interactions between oncogenic 
signaling and cellular metabolism (5, 6). PCho is both a precur-
sor and a breakdown product of phosphatidylcholine (PC), one 
of the major components of cellular membranes. Indeed, the 
PCho content is sustained by activation of enzymes involved in 
PC biosynthetic and catabolic pathways: choline kinase (ChoK) 
and PC-specific phospholipase C (PC-PLC) (Figure 1A). ChoK 
is the first enzyme of the Kennedy pathway responsible for 
catalyzing the phosphorylation of free choline to form PCho in 
the biosynthesis of PC (7). Three isoforms of ChoK are present in 
mammalian cells encoded by two different genes: choline kinase-
alpha (CHKA) and choline kinase-beta (CHKB). However, 
only ChoK-alpha (ChoK-α) has a central role in sustaining PC 
biosynthesis required for the uncontrolled growth of cancer 
cells, and ChoK-β alone cannot compensate this activity (8). 
In addition to its metabolic function, ChoK-α has been proven 
to play a critical role in oncogenesis, tumor progression, and 
metastasis of several cancers being required for the activation of 
growth factor-triggered signaling pathways (Ras activation, PI3K 
signaling), roles that proposed CHKA as an oncogene (5, 9–11). 
Indeed, an altered choline metabolism, sustained by increased 
expression and activity of ChoK-α, has been reported in various 
human malignancies (12–19). Furthermore, in the case of early 
stage non-small cell lung cancer (20), early stage hepatocellular 
carcinoma (21), and prostate cancer (22), a  prognostic role of 
ChoK-α overexpression has been revealed. These observations 
provided the molecular basis for the development of non-
invasive imaging approaches based on choline phosphorylation 
for the characterization of tumor growth and response to therapy 
(23–26) as well as the rationale for developing specific inhibitors 
for this metabolic pathway even in diseases other than cancer 
(27, 28).
CHOLine KinASe AS A POTenTiALLY 
new THeRAPeUTiC TARGeT FOR 
CAnCeR TReATMenT
Choline kinase-α is an enzyme of particular interest being at 
the crossroad of the main survival signaling pathways with 
its overexpression contributing, through a positive feedback 
loop, to increased MAPK and PI3K signaling (5, 29). A large 
body of work in cancer cells suggests that ChoK-α expression 
and activity is directly associated not only with increased 
cancer cell proliferation but also with malignancy, making it a 
potential novel target for image-guided cancer therapy. In fact, 
the targeting of ChoK-α by RNA interference (RNAi) results 
in decreased PCho and tCho levels in human breast cancer 
cells while leaving human mammary epithelial cells unaffected 
(30, 31), thus opening an important therapeutic window for 
the development of a pharmacological intervention directed to 
this enzyme (32, 33). Indeed, the antitumor effects of ChoK-α 
inhibition has been reported in various cancers (34–40). 
Different compounds are at the moment available for ChoK-α 
pharmacological inhibition: hemicholinium-3 (HC-3), a 
competitive inhibitor with a ChoK-α mimetic structure able to 
block also choline transport, is very efficient in vitro but highly 
toxic in  vivo (41); MN-58b, not commercially available, is a 
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less toxic HC-3 derivative able to inhibit cell growth in vivo in 
animal models (42); RSM-932A, a Chok-α inhibitor selected 
for further clinical development due to its potent in  vivo 
anticancer activity and lack of toxicity at the effective doses 
(43); CK37, a small molecule able to inhibit tumor growth in 
preclinical models (44); and new small molecule inhibitors 
identified by fragment-based drug discovery (45). These data 
suggest that inhibiting ChoK-α, even in combination with 
standard chemotherapeutic treatments, might represent a new 
anticancer approach particularly in tumors such as ovarian 
cancer with a still open clinical need for the identification of 
more efficient therapeutic modalities.
OvARiAn CAnCeR
Epithelial ovarian cancer (EOC) is a life-threatening disease 
characterized by late-stage presentation and a distinctive ability 
to heavily invade the abdominal cavity (46). The yearly worldwide 
incidence of this cancer is of 238,700 new cases with a global 
mortality of 151,900 deaths per year (47), which make EOC the 
leading cause of death for gynecological cancers. Standard treat-
ment for EOC patients is an aggressive primary surgery followed 
by platinum-based chemotherapy. However, around 30% of the 
patients undergo chemotherapeutic treatments before being 
identified as chemoresistant, and even for patients who achieve 
a pathological complete response, maintaining disease-free 
status remains a challenge. Indeed, most of the patients develop 
platinum-resistant recurrent disease, a largely incurable state. 
Despite the impressive improvement of surgical approaches and 
drug development, survival rate has changed little in the last 
decades (48), and 5-year survival rate for advanced stage patients 
is still around 30% (49).
It is well known that resistance to chemotherapy is one of the 
tumor “hallmarks” that also includes tumor ability to modify/
reprogram cellular metabolism (1) to face with the biosynthetic 
demand of rapid proliferation and to overcome metabolic stress 
imposed by the microenvironment. As for many other cancer 
types, also EOC cells become dependent on these metabolic 
changes, which could be possibly exploited to identify therapeutic 
targets for overcoming chemoresistance.
TARGeTinG THe ALTeReD CHOLine 
MeTABOLiSM TO evADe/CiRCUMvenT 
eOC CHeMOReSiSTAnCe
Aberrant choline metabolism has been recently defined also in 
EOC. Analysis of expanded tCho MR spectral profiles showed 
that the relative areas of signal components due to individual 
choline metabolites [glycerophosphocoline (GPC), PCho, and 
free choline] changed in the progression from non-tumoral 
ovarian surface epithelial cells (OSE) or immortalized cell vari-
ants to EOC cells (15), with the PCho relative signal becoming 
predominant in carcinoma cells (Figure 1B).
A large body of work demonstrated that, in EOC, these altera-
tions are sustained by the activation of two enzymes ChoK-α 
and PC-PLC, respectively, involved in the PC biosynthetic and 
catabolic pathway. ChoK-α has a major role in increasing PCho 
content. Indeed, ChoK-α is overexpressed and hyperactivated in 
EOC cells as compared with the normal counterpart, account-
ing for up to the 70–80% of the total intracellular PCho content 
(16,  37). Gene expression analysis of the enzymes involved in 
the PC anabolic pathway showed that only CHKA was overex-
pressed, whereas the expression of other enzymes involved in 
the Kennedy pathway, as well as the beta isoform of choline 
kinase (CHKB), choline transporters, and enzymes involved in 
some catabolic pathways (mediated by PLD, PLA1, and PLA2) 
remained essentially unchanged (16). Among the enzymes 
involved in catabolic pathways, only PC-PLC is directly involved 
in PCho production. Although the mammalian PC-PLC has not 
been currently cloned and its sequence is unknown, this enzyme 
has been shown to be overexpressed and hyperactivated in EOC 
cells compared with normal counterparts (16, 50). EOC cells 
exposure to the PC-PLC inhibitor D609 abolished the activity of 
this enzyme and reduced the intracellular PCho level (without 
altering GPC and free choline contents), suggesting that also 
PC-PLC partially contributes to the intracellular PCho pool in 
EOC (16, 50).
To define the role of the abnormal expression and increased 
activation of ChoK-α in EOC biology, the enzyme was inactivated 
by transient and stable RNA interference in EOC cell lines and 
in non-tumoral immortalized cell variants. ChoK-α inhibi-
tion resulted in a less aggressive phenotype (36, 37), causing a 
decreased cell proliferation both in vitro and in preclinical in vivo 
models of Nu/Nu mice, an impaired capability to migrate and 
invade, together with an increased sensitivity to drug treatment 
of EOC cells (Figure 2).
The effects related to CHKA targeting in EOC appeared 
to induce a perturbation on EOC cell behavior different than 
that observed in other cellular models. In fact, neither previ-
ously described reduction of Akt phosphorylation in a PI3K-
independent way (51) nor an attenuation of MAPK and PI3K/
AKT signaling (29) was observed. Furthermore, in spite of a 
reduced cell proliferation, neither a decrease of cell viability nor 
apoptosis was detected in CHKA-silenced EOC cells.
On the other hand, the analysis of global metabolic profiling 
identified an altered glutathione (GSH) metabolism characterized 
by a decreased cysteine and GSH content (37). GSH is a thiol pep-
tide involved in regulation of cell redox status through its antioxi-
dant activities (52). Reduction of GSH content, perturbing redox 
homeostasis, is expected to render tumor cells more susceptible 
to chemotherapeutic treatment (Figure 2), and high intracellular 
levels of reduced GSH have been shown to contribute in develop-
ing resistance to chemotherapeutic drugs including platinum and 
doxorubicin (53–55). Accordingly, CHKA targeting in different 
EOC cellular models increased reactive oxygen species (ROS) 
intracellular levels and sensitivity to platinum and doxorubicin 
treatment. These effects were mediated by the reduction of GSH 
content, even in a drug resistant EOC model, while leaving unaf-
fected the non-tumoral immortalized epithelial ovarian cells (37) 
(Figure 2).
Interestingly, the critical enzyme cleaving GPC to produce 
choline, the initial step in the pathway controlling the GPC/
PC ratio, has been recently identified (56). The enzyme, named 
FiGURe 2 | effects of CHKA silencing in eOC cell lines. CHKA silencing decreases cell proliferation in vitro and in vivo in preclinical models, impairs the 
capability of EOC cells to migrate and invade, and decreases levels of intracellular GSH, thus impairing cellular redox homeostasis and therefore increasing EOC, but 
not IOSE-HTERT sensitivity to platinum treatment.
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endometrial differential 3 (EDI3), was initially described in a 
breast cancer cell line, where its inhibition corrected the GPC/PC 
ratio and reduced migratory activity of tumor cells. Also, EDI3 
overexpression was associated with higher risk of developing 
metastasis and decreased survival in endometrial and ovarian 
cancer (56). The recent finding that EDI3 links choline metabo-
lism to integrin expression, cell adhesion, and spreading also in 
an EOC cell line (57), suggests EDI3 as a new possible target to be 
explored, further confirming the value of the choline metabolism 
for therapeutic intervention in EOC.
The EOC “cholinic phenotype” is a peculiar feature of trans-
formed cells that recapitulates the addiction of EOC cells to 
GSH content for the maintenance of their antioxidant defense. 
Targeting mechanisms upon which cancer cells are expected 
to be dependent (CHKA expression and cellular ROS homeo-
stasis) could explain the differential response of cancer and 
 non-transformed cells to CHKA knockdown. As well known, 
cancer cells acquire specific genetic and epigenetic alterations 
that involve hyperactivation of oncogenes and/or inactivation 
of oncosuppressor genes. Some genetic changes support survival 
of cancer cells by creating specific signaling, which sustain 
metabolic pathways. However, the overall deregulation of cellular 
processes and functions is frequently associated with enhanced 
cellular stress, and malignant cells have to adapt to this pheno-
type, becoming dependent on a number of non-oncogenic func-
tions to survive (3). Similarly, a dependency associated with ROS 
homeostasis has been shown to constitute a selective liability of 
malignant cells also in xenograft tumor models (58). Identifying 
such dependencies represent a promising alternative for the 
development of new therapeutic strategies to successfully target 
metabolic enzymes minimizing adverse effects on normal tissues. 
Synergisms of choline metabolism knockdown with conventional 
treatment might open an interesting clinical perspective, as it 
could represent an alternative strategy to increase the treatment 
efficacy also by reducing the clinical dose of drugs and limiting 
the damage of normal cells.
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eXPLOiTinG THe ALTeReD CHOLine 
MeTABOLiSM FOR THe IN VIVO iMAGinG 
OF TUMOR ReSPOnSe TO THeRAPieS
Due to the increased metabolic activity, tumors are expected to 
intake greater amounts of a radioactive tracer than the adjacent 
normal tissues, justifying the use of PET imaging to monitor 
response to treatment and disease recurrence (59). Accordingly, 
the increased expression and activity of ChoK-α and choline 
transporters in tumor cells promoted a rapid development 
of radiolabeled choline analogs, as PET imaging tracers and 
11C- or 18F-choline were proven to be more effective than 
18F-fluorodeoxyglucose (FDG), whose abundant radioactivity 
excretion into the bladder could hamper image interpretation. 
Indeed, in the case of radiolabeled choline analogs, their incor-
poration mainly reflects the total amount of radiotracer that 
enters the cell by choline transport and accumulates, by efficient 
phosphorylation mainly due to ChoK activation, in the pool of 
water-soluble intermediates of the Kennedy pathway (24). Within 
the time window of choline PET examinations, the contributions 
given by PC catabolic enzymes (such as phospholipases C and D) 
to the pool of these radiolabeled choline derivatives are instead 
negligible (6).
The large proportion of studies evaluating choline radiotrac-
ers has been conducted in prostate cancer where choline PET 
gave a clinical contribution in the diagnosis and monitoring of 
response to therapy; however, the utility of 11C- or 18F-choline as 
radiotracers has been extensively reported also in non-prostate 
histotypes  (24, 59). Although studies on 11C- or 18F-choline as 
radiotracers in PET examinations of genitourinary tract cancers 
are currently under active evaluation as an alternative to 18F-FDG, 
few studies are currently available on the use of choline-based 
tracer in ovarian cancer, even at preclinical level (60, 61).
In spite of the EOC cholinic phenotype, a choline-based non-
invasive detection and management is still a relatively unexplored 
field in this disease. An improvement in instrumentation and 
the integration of different imaging approaches, such as PET, 
magnetic resonance imaging (MRI), and computed tomography 
(CT), could provide the unique opportunity to monitor both 
morphologic and metabolic changes in tumor to improve diag-
nosis and the assessment of therapeutic efficacy.
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